Key facts
- It has raised $149.0M across 1 recorded rounds; the latest was Early Stage VC (Series B) ($149.0M) in Dec 2022.
- 5 institutional filers report fund marks on Apogee Therapeutics across 50 filings.
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Apogee Therapeutics
Create free account
No card required
Funding rounds
1 roundsDec 2022Early Stage VC (Series B)$149.0M▮
About Apogee Therapeutics
- Industry
- Biotechnology
PA Mark — not yet priced
Apogee Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Apogee Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
5 filers · latest May 20265 SEC-registered funds reported 50 fair-value marks on Apogee Therapeutics between Apr 2025 and May 2026. Filer-level marks and implied $/share are available to Pro members.